<DOC>
	<DOCNO>NCT00895596</DOCNO>
	<brief_summary>The purpose study investigate safety antiviral activity ascend multiple oral dos LB80380 12 week adults lamivudine-refractory chronic hepatitis B infection .</brief_summary>
	<brief_title>Safety Efficacy Study LB80380 Patients With Lamivudine-Refractory Chronic Hepatitis B</brief_title>
	<detailed_description>LB80380 , oral prodrug , promise candidate nucleoside analogue antiviral activity wild-type HBV . LB80380 undergo clinical development LG Life Sciences use treatment chronic HBV infection treatment lamivudine-resistant disease . In study , treatment period divide two part : 4-week treatment period dose escalation assessment ( Part 1 ) , follow 8-week extension period ( Part 2 ) . During Part 1 , patient receive LB80380 LVD 100 mg daily 4 week . Each patient give LB80380 additional 8 week ( Part 2 ) unless dose-limiting toxicity ( DLT ) observe Part 1 . At dose level , patient complete least Part 1 treatment period enrolment next Dose Group could commence . Dose escalation next group initiate two patient experience DLT Part 1 previous Dose Group . Additionally , patient enrol LB80380 150mg 240mg group agree participate pharmacokinetic ( PK ) analyse visit study site day Week 12 blood sampling . Follow-up period 24 week , patient treat adefovir dipivoxil follow-up period . During study , patient evaluate change baseline serum HBV DNA . Safety evaluate basis occurrence AEs change baseline clinical laboratory parameter , physical examination finding , vital sign .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Compensated chronic hepatitis B patient Presence serum HBsAg 6 month . Presence HBeAg 1 month compensate liver disease Confirmation YMDD mutant ( M552V , M552I relate double mutant L528M ) genotyping YMDD motif use line probe assay ( INNOLiPA HBV DR assay ) Screening HBV DNA value high equal 1,000,000 copies/mL ( measure COBAS Amplicor HBV Monitorâ„¢ assay ) Screening ALT value 1.5 10 x ULN Coinfection hepatitis C D virus ( HCV HDV ) HIV Pregnancy breastfeed Previous treatment nucleoside analogue treatment HBV except lamivudine within 6 month prior study entry Treatment immunomodulatory agent corticosteroid within 6 month prior study entry . Decompensated liver disease Screening alphafetoprotein ( AFP ) value &gt; 20 ng/mL , followup ultrasonography perform prior baseline show finding indicative HCC . Presence antiHBs screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Lamivudine resistant</keyword>
	<keyword>YMDD mutant type</keyword>
</DOC>